3T Biosciences

Executive Summary

3T Biosciences is a clinical-stage immunotherapy company pioneering next-generation T-cell receptor (TCR)-based therapeutics for solid tumors and immune-mediated diseases. Leveraging its proprietary 3T-TRACE discovery platform, the company systematically identifies novel tumor-specific targets and engineers highly selective TCR-derived therapies to overcome key bottlenecks in targeted biotherapeutics. By focusing on broad patient populations, 3T aims to address significant unmet needs in oncology. The company is privately held and based in South San Francisco, with no disclosed total funding or valuation as of the last update.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 Clinical Data Readout for Lead TCR-T Candidate60% success
• Q4 2026Announcement of New Strategic Partnership or Licensing Deal50% success
• Q1 2027Series C Financing or Major Funding Round70% success